Systemic therapy, including chemotherapy, hormonal therapy, and HER2-targeted treatment, constituted the mainstay of management, with surgical intervention reserved for palliation or local control.Breast cancer metastases to rare sites pose significant diagnostic challenges, often mimicking synchronous primary tumors of the affected organs. This evidence concerns the gene ERBB2 and breast carcinoma.